MedTrace Logo

Combination Chemotherapy Followed By Vaccine Therapy Plus Sargramostim in Treating Patients With Stage III or Stage IV Non-Hodgkin's Lymphoma

NCT00017290 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL

Last updated 2013-12-04

No results posted yet for this study

Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Vaccines may make the body build an immune response to kill cancer cells. It is not yet known which regimen of chemotherapy combined with vaccine therapy is more effective for non-Hodgkin's lymphoma.

PURPOSE: Randomized phase III trial to determine the effectiveness of combination chemotherapy followed by vaccine therapy plus sargramostim in treating patients who have stage III or stage IV non-Hodgkin's lymphoma.

Conditions

Interventions

BIOLOGICAL

autologous immunoglobulin idiotype-KLH conjugate vaccine

BIOLOGICAL

keyhole limpet hemocyanin

BIOLOGICAL

sargramostim

DRUG

cyclophosphamide

DRUG

prednisone

DRUG

vincristine sulfate

Sponsors & Collaborators

  • Genitope Corporation

    lead INDUSTRY

Principal Investigators

  • David Hinds · Genitope Corporation

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2000-11-30

Countries

  • United States
  • Canada

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00017290 on ClinicalTrials.gov